Two parallel phase 2 nonrandomized clinical trials demonstrated a median PFS of 5.7 months and an OS of 13.6 months with olaparib monotherapy in patients with pretreated, advanced pancreatic cancer with DNA damage repair genetic alterations other than the germline BRCA variant, including gATM, sATM, gPALB2, sARID1A, sBRCA, sPTEN, sRAD51, sCCNE, and sFANCB. This evidence concerns the gene GATM and pancreatic neoplasm.